Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 4/2012

01.08.2012 | PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

How Can Psoriatic Arthritis Be Diagnosed Early?

verfasst von: Amir Haddad, Vinod Chandran

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthritis that usually develops after the onset of cutaneous psoriasis. Early diagnosis of PsA may lead to less joint damage and better long-term outcomes. Identifying inflammatory arthritis in individuals with psoriasis is the key to early diagnosis of PsA. Screening strategies targeted at individuals with psoriasis, as well as family members of patients with PsA will result in early identification of PsA. This article describes the various strategies that could be employed to identify inflammatory arthritis in patients with psoriasis so that appropriate referral to a rheumatologist for early diagnosis of PsA may be made.
Literatur
1.
Wright V, Moll JMH. Psoriatic arthritis. In Seronegative polyarthritis. North Holland Publishing Co. 1976: 169–223.
2.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.PubMedCrossRef
3.
Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2007;57:1560–3.PubMedCrossRef
4.
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314–21.PubMedCrossRef
5.
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.
6.
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.PubMedCrossRef
7.
Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61:1373.PubMedCrossRef
8.
Gladman DD. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol. 1994;8:379–94.PubMedCrossRef
9.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med. 1987;62:127–41.PubMed
10.
Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.PubMed
11.
Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.CrossRef
12.
Poole CD, Lebmeier M, Ara R, Rafia R, Currie CJ. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford). 2010;49:1949–56.CrossRef
13.
Wong K, Gladman DD, Husted J, Long J, Farewell VT. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and Causes of Death. Arthritis Rheum. 1997;40:1873–7.CrossRef
14.
Ali Y, Tom BDM, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum. 2007;56:2708–14.PubMedCrossRef
15.
Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis. Results from a single centre. II. Prognostic factors for death. Arthritis Rheum. 1998;41:1103–10.PubMedCrossRef
16.
Gladman DD. Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, editors. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag; 2005. p. 118–23.CrossRef
17.
• Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70:2152–4. Disease progression is more marked in patients presenting with established disease of more than 2 years’ duration. These results suggest that patients with PsA should be treated earlier in the course of their disease.PubMedCrossRef
18.
Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol. 2009;23:683–91.PubMedCrossRef
19.
Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040–7.PubMedCrossRef
20.
• Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, Sato R, Boggs R. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548–54. In contrast to the prevailing notion that the greatest risk of developing PsA is during the first years following the onset of psoriasis, this retrospective report from Europe has shown that the rate of development of PsA among psoriasis patients is constant and unrelated to the duration of psoriasis.PubMedCrossRef
21.
• Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, Gladman DD. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63:619–22. In contrast to the prevailing notion that the greatest risk of developing PsA is during the first years following the onset of psoriasis, this prospective report has shown that the rate of development of PsA among psoriasis patients is constant and unrelated to the duration of psoriasis.CrossRef
22.
• Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, Rahman P, Gladman DD. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009;68:664–7. An increase in risk of developing PsA in first-degree relatives of patients with PsA indicates that targeted screening of family members is a strategy for early diagnosis.PubMedCrossRef
23.
• Karason A, Love TJ, Gudbjornsson B. A strong heritability of psoriatic arthritis over four generations—the Reykjavik Psoriatic Arthritis Study. Rheumatology (Oxford). 2009;48:1424–8. An increase in risk of developing PsA in first- to fourth-degree relatives of patients with PsA indicates that targeted screening of family members is a strategy for early diagnosis.CrossRef
24.
Chandran V, Gladman DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep. 2010;12:288–94.PubMedCrossRef
25.
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–9. Erratum in: Arthritis Rheum 2010;62:574.PubMedCrossRef
26.
Dominguez P, Gladman DD, Helliwell P, Mease PJ, Husni ME, Qureshi AA. Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep. 2010;12:295–9.PubMedCrossRef
27.
Khraishi M, Mong J, Mugford G, Landells I. The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients. J Cutan Med Surg. 2011;15:143–9.PubMed
28.
Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581–7.PubMedCrossRef
29.
Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res. 2009;301:573–9.PubMedCrossRef
30.
Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469–74.PubMed
31.
Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, Farewell VT. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68:497–501.PubMedCrossRef
32.
Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2012;Jan 25. [Epub ahead of print] PubMed PMID: 22274791.
33.
• Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, Gladman DD. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2012;71:50–5. HLA-B*08, -B*27, -B*38, and HLA-C*06 alleles confer susceptibility to PsA among patients with psoriasis and may be used to identify patients with PsC who may develop PsA.PubMedCrossRef
34.
• Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, Fitzgerald O. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2011. doi:10.​1002/​art.​33415. Patients with PsA carrying the HLA-B*27 allele have temporally more coincident musculoskeletal disease. HLA-B*08, -B*27, and HLA-C*06 alleles confer susceptibility to PsA among patients with psoriasis and may be used to identify patients with PsC who may develop PsA.
35.
Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR. Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41:199–204.PubMedCrossRef
36.
Gladman DD, Chandran V. Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future? Curr Rheumatol Rep. 2011;13:346–52.PubMedCrossRef
37.
Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford). 2008;47:718–23.CrossRef
38.
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159:322–30.PubMedCrossRef
39.
Alenius GM, Eriksson C, Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol. 2009;27:120–3.PubMed
40.
Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, Rosen CF, Gladman DD. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford). 2010;49:1399–405.CrossRef
41.
Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.PubMed
42.
• Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther. 2010;12:R14. CD16 has the potential to serve as a marker for osteoclast precursors in inflammatory arthritis.PubMedCrossRef
43.
McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56:2482–91.PubMedCrossRef
44.
Erdem CZ, Tekin NS, Sarikaya S, et al. MR imaging features of foot involvement in patients with psoriasis. Eur J Radiology. 2008;68:521–5.CrossRef
45.
Gisondi P, Tinazzi I, El-Dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis. 2008;67:26–30.PubMedCrossRef
46.
Raza N, Hameed A, Ali MK. Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate. Clin Exp Dermatol. 2008;33:70–3.PubMedCrossRef
47.
Tan AL, Grainger AJ, Taneer SF, Emery P, Mcgonagle D. A high resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 2006;54:1328–33.PubMedCrossRef
48.
Bennett AN, Rehman A, Hensor EM, Marzo-ortega H, Emery P, Mcgonagle D. Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondyloarthritis. Arthritis Rheum. 2009;60:1331–41.PubMedCrossRef
49.
• Tinazzi I, McGonagle D, Biasi D, Confente S, Caimmi C, Girolomoni G, Gisondi P. Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol. 2011;38:2691–2. This follow-up study indicates that patients with psoriasis who have higher enthesopathy score may be at higher risk of developing PsA.PubMedCrossRef
50.
• Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M, Gisondi P, Tan AL, Marzo-Ortega H, Emery P, Wakefield RJ, McGonagle DG, Aydin SZ. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012;71:553–6. A link between nail disease and contemporaneous subclinical enthesopathy offers a novel anatomic basis for the predictive value of nail psoriasis for PsA evolution.PubMedCrossRef
51.
Mandl P, Niedermayer DS, Balint PV. Ultrasound for enthesitis: handle with care! Ann Rheum Dis. 2012;71:477–9.PubMedCrossRef
Metadaten
Titel
How Can Psoriatic Arthritis Be Diagnosed Early?
verfasst von
Amir Haddad
Vinod Chandran
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 4/2012
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-012-0262-6

Weitere Artikel der Ausgabe 4/2012

Current Rheumatology Reports 4/2012 Zur Ausgabe

SYSTEMIC LUPUS ERYTHEMATOSUS (JT MERRILL, SECTION EDITOR)

Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Treatment Algorithms for Early Psoriatic Arthritis: Do They Depend on Disease Phenotype?

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Altered Bone Biology in Psoriatic Arthritis

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives

SYSTEMIC LUPUS ERYTHEMATOSUS (JT MERRILL, SECTION EDITOR)

Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?

SYSTEMIC LUPUS ERYTHEMATOSUS (JT MERRILL, SECTION EDITOR)

The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise